Published in Dig Dis Sci on October 01, 2005
Primary sclerosing cholangitis--what is the difference between east and west? World J Gastroenterol (2008) 0.88
Secondary Sclerosing Cholangitis and Hodgkin's Lymphoma. Clin Med Insights Case Rep (2015) 0.75
High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med (2001) 12.49
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology (1989) 2.39
Primary sclerosing cholangitis. N Engl J Med (1995) 1.94
PERICHOLANGITIS AND ULCERATIVE COLITIS. I. PATHOLOGY, ETIOLOGY, AND PATHOGENESIS. Ann Intern Med (1965) 1.87
Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology (1992) 1.51
A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc (2000) 1.45
PERICHOLANGITIS AND ULCERATIVE COLITIS. II. CLINICAL ASPECTS. Ann Intern Med (1965) 1.00
Primary sclerosing cholangitis. Complete gross and histologic reversal after long-term steroid therapy. Am J Gastroenterol (1970) 0.95
Azathioprine in primary sclerosing cholangitif. Lancet (1971) 0.95
Azathioprine treatment in primary sclerosing cholangitis. Lancet (1971) 0.86
Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann Intern Med (1999) 0.82
Primary sclerosing cholangitis and low-dose oral pulse methotrexate therapy. Clinical and histologic response. Ann Intern Med (1987) 0.81
Treatment of primary sclerosing cholangitis with oral methotrexate. Am J Gastroenterol (1991) 0.80
Medical approaches to primary sclerosing cholangitis. Semin Liver Dis (1991) 0.77
Is primary sclerosing cholangitis a progressive disease or not? Hepatology (1988) 0.75
Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet (2006) 8.32
Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis (2002) 5.34
A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell (2012) 4.49
A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe (2009) 4.24
Hepatic portal venous gas: the ABCs of management. Arch Surg (2009) 3.76
Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest (2003) 3.40
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology (2004) 2.91
CD8 epitope escape and reversion in acute HCV infection. J Exp Med (2004) 2.77
Case records of the Massachusetts General Hospital. Case 23-2005. A 57-year-old man with a mass in the liver. N Engl J Med (2005) 2.67
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology (2008) 2.45
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int (2009) 2.33
Development of an accurate index for predicting outcomes of patients with acute liver failure. Gastroenterology (2012) 2.26
Alanine aminotransferase levels: what's normal? Ann Intern Med (2002) 2.17
Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology (2005) 2.15
Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology (2009) 2.13
Viral sequence evolution in acute hepatitis C virus infection. J Virol (2007) 2.13
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology (2011) 2.08
The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients. Clin Infect Dis (2006) 2.08
Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol (2002) 2.03
Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood (2008) 2.01
High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. J Virol (2007) 2.01
Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol (2002) 1.98
Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA (2008) 1.94
Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol (2006) 1.87
Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology (2005) 1.87
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Coinfection with HIV-1 and HCV--a one-two punch. Gastroenterology (2009) 1.78
Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl (2005) 1.76
Influence of high body mass index on outcome in acute liver failure. Clin Gastroenterol Hepatol (2006) 1.74
Non-high-density lipoprotein cholesterol as a biomarker for nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2012) 1.74
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology (2006) 1.73
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression. Gastroenterology (2003) 1.68
Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest (2002) 1.65
IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol (2010) 1.64
GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype. J Infect Dis (2006) 1.64
HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology (2008) 1.60
Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol (2005) 1.59
Gc-globulin and prognosis in acute liver failure. Liver Transpl (2005) 1.59
Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol (2005) 1.54
The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood (2004) 1.53
Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol (2002) 1.52
Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology (2010) 1.51
Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology (2010) 1.51
Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance. Liver Transpl (2008) 1.50
Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis (2009) 1.49
Management strategies using pharmacogenomics in patients with severe HCV-1b infection: a decision analysis. Hepatology (2002) 1.47
Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus. Hepatology (2014) 1.46
Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology (2007) 1.44
Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology (2005) 1.44
Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med (2012) 1.43
A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus. J Hepatol (2011) 1.41
A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Gastroenterology (2006) 1.40
Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol (2002) 1.40
Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med (2006) 1.36
Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in Hepatitis C virus infection outcome. Mol Immunol (2008) 1.36
Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer (2007) 1.30
Serum apoptosis markers in acute liver failure: a pilot study. Clin Gastroenterol Hepatol (2007) 1.29
Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology (2005) 1.26
HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. J Biol Chem (2010) 1.24
Anti-hepatitis C virus drugs in development. Gastroenterology (2012) 1.23
Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int (2010) 1.22
Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation (2004) 1.22
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology (2009) 1.18
Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol (2004) 1.18
Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV/HCV-coinfected persons. J Infect Dis (2005) 1.14
Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy. J Infect Dis (2004) 1.14
Pathogenesis of accelerated fibrosis in HIV/HCV co-infection. J Infect Dis (2013) 1.14
IgG4-associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material. Mod Pathol (2009) 1.11
Acute liver failure: mechanisms of hepatocyte injury and regeneration. Semin Liver Dis (2008) 1.09
Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol (2006) 1.08
De novo autoimmune hepatitis during immune reconstitution in an HIV-infected patient receiving highly active antiretroviral therapy. Clin Infect Dis (2008) 1.07
HCV and host lipids: an intimate connection. Semin Liver Dis (2013) 1.06
Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling. J Virol (2012) 1.06
Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol (2008) 1.06
A genetic screen identifies interferon-α effector genes required to suppress hepatitis C virus replication. Gastroenterology (2013) 1.06
Treatment of recurrent allograft dysfunction with intravenous hematin after liver transplantation for erythropoietic protoporphyria. Transplantation (2002) 1.05
An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One (2011) 1.04
Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology (2007) 1.03
Novel therapies for hepatitis C: insights from the structure of the virus. Annu Rev Med (2011) 1.03
Protein kinase R is increased and is functional in hepatitis C virus-related hepatocellular carcinoma. Am J Gastroenterol (2003) 1.03
Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl (2004) 1.02
Treatment failure in hepatitis C: mechanisms of non-response. J Hepatol (2008) 1.02
Aerobic capacity is associated with 100-day outcome after hepatic transplantation. Liver Transpl (2004) 1.00
Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. Hepatology (2005) 0.99
Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner. J Virol (2010) 0.99
Intrahepatic cytokine expression is downregulated during HCV/HIV co-infection. J Med Virol (2006) 0.99
High antibody level: an accurate serologic marker of viremia in asymptomatic people with hepatitis C infection. Transfusion (2010) 0.99
Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. J Hepatol (2009) 0.98
AAHA senior care guidelines for dogs and cats. J Am Anim Hosp Assoc (2005) 0.98
Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection. Blood (2007) 0.98
ARF1 and GBF1 generate a PI4P-enriched environment supportive of hepatitis C virus replication. PLoS One (2012) 0.98
Pretransplant depression, antidepressant use, and outcomes of orthotopic liver transplantation. Liver Transpl (2011) 0.98
Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C). J Acquir Immune Defic Syndr (2010) 0.97